Noramco
Noramco
Noramco
  • About Us
    • About Noramco
    • Our People
    • Leadership
    • Excellence in Compliance
    • Minimizing Risk
  • Products & Solutions
    • Active Pharmaceutical Ingredients
      • Active Pharmaceutical Ingredients
      • Nal Family of Antagonists
      • ADHD / Stimulants
      • Full Product List
    • Noramco Solutions
      • Noramco Solutions
      • Clinical Supply
      • Controlled Substance Building Blocks and Intermediates
    • Platform Technologies
      • Platform Technologies
      • Platform Technology: Custom Synthesis
    • Reference Standards
      • Reference Standards
      • Reference Standards: Custom Synthesis
    • Reference Standards Store
  • Careers
  • News & Events
    • News & Events
    • Press Releases
  • Contact

Sort by

  • Default sorting
  • Sort by popularity
  • Sort by newness
  • Sort by price: low to high
  • Sort by price: high to low

View

  • 9 items
  • 15 items
  • 30 items

Showing 10–18 of 20 results

  • 46_Cannabigerolic-Acid-(CBGA)
    Quick ViewSelect options

    Cannabigerolic Acid (CBGA)

    $3,750.00 – $13,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 25555-57-1 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2186-**
    Quick ViewSelect options
  • 55_Cannabinol-(CBN)
    Quick ViewSelect options

    Cannabinol (CBN)

    $2,500.00 – $9,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 521-35-7
    Quick ViewSelect options
  • 54_Exo-Tetrahydrocannabinol
    Quick ViewSelect options

    Exo-Tetrahydrocannabinol

    $2,500.00 – $9,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 27179-28-8
    Quick ViewSelect options
  • 47_8-Tetrahydrocannabinol
    Quick ViewSelect options

    Δ8-Tetrahydrocannabinol

    $30.00 – $2,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 5957-75-5 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2161-**
    Quick ViewSelect options
  • 49_8-Tetrahydrocannabinol-Naphthoylester
    Quick ViewSelect options

    Δ8-Tetrahydrocannabinol Naphthoylester

    $2,500.00 – $9,500.00
    <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2198-**
    Quick ViewSelect options
  • 40_9-Tetrahydrocannabiarinic-Acid-(THCVA)
    Quick ViewSelect options

    Δ9-Tetrahydrocannabiarinic Acid (THCVA)

    $3,750.00 – $13,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 39986-26-0 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2188-**
    Quick ViewSelect options
  • 33_9-Tetrahydrocannabinol-(THC)
    Quick ViewSelect options

    Δ9-Tetrahydrocannabinol (THC)

    $30.00 – $2,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 1972-08-3 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2160-**
    Quick ViewSelect options
  • 56_9-Tetrahydrocannabinol-(THC)-Methyl-Analogue
    Quick ViewSelect options

    Δ9-Tetrahydrocannabinol (THC)-Methyl Analogue

    $2,500.00 – $9,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 172301-79-0
    Quick ViewSelect options
  • 48_9-Tetrahydrocannabinol-Naphthoylester
    Quick ViewSelect options

    Δ9-Tetrahydrocannabinol Naphthoylester

    $2,500.00 – $9,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 874200-77-8 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2199-**
    Quick ViewSelect options
  • 1
  • 2
  • 3

Recent Articles

  • Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
  • Diversifying the Supply of Raw Materials
  • Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
  • Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
  • Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
Copyright 2025 Noramco. All Rights Reserved. Contact | Legal Notice | Privacy Policy | Terms & Conditions | Benefits Transparency Mandate